These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 26004006)
1. Characterization of 9-nitrocamptothecin-in-cyclodextrin-in-liposomes modified with transferrin for the treating of tumor. Chen J; Lu S; Gu W; Peng P; Dong J; Xu F; Yang X; Xiong Z; Yang X Int J Pharm; 2015 Jul; 490(1-2):219-28. PubMed ID: 26004006 [TBL] [Abstract][Full Text] [Related]
2. Delivery of fluorescent-labeled cyclodextrin by liposomes: role of transferrin modification and phosphatidylcholine composition. Chen J; Yao J; Ma Z; Peng P; Lu S; Hu Y; Xu F; Yang Y; Yang X J Liposome Res; 2017 Mar; 27(1):21-31. PubMed ID: 26911560 [TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Li X; Ding L; Xu Y; Wang Y; Ping Q Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296 [TBL] [Abstract][Full Text] [Related]
4. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. Hong M; Zhu S; Jiang Y; Tang G; Pei Y J Control Release; 2009 Jan; 133(2):96-102. PubMed ID: 18840485 [TBL] [Abstract][Full Text] [Related]
5. Drug-in-cyclodextrin-in-liposomes: a promising delivery system for hydrophobic drugs. Chen J; Lu WL; Gu W; Lu SS; Chen ZP; Cai BC; Yang XX Expert Opin Drug Deliv; 2014 Apr; 11(4):565-77. PubMed ID: 24490763 [TBL] [Abstract][Full Text] [Related]
6. Complex of 9-nitro-camptothecin in hydroxypropyl-beta-cyclodextrin: in vitro and in vivo evaluation. Jiang Y; Sha X; Zhang W; Fang X Int J Pharm; 2010 Sep; 397(1-2):116-21. PubMed ID: 20637848 [TBL] [Abstract][Full Text] [Related]
7. Transferrin coupled vesicular system for intracellular drug delivery for the treatment of cancer: development and characterization. Vaidya B; Vyas SP J Drug Target; 2012 May; 20(4):372-80. PubMed ID: 22339366 [TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy, toxicity and pharmacokinetics of 9-nitrocamptothecin: role of lactone ratio. Chen J; Hu RR; Yang XX; Gu W; Tian R; Gong F; Luo L; Fang F; Chen ZP; Cai BC Cancer Chemother Pharmacol; 2013 Oct; 72(4):925-9. PubMed ID: 23934323 [TBL] [Abstract][Full Text] [Related]
9. Preparation, characterization, pharmacokinetics, and bioactivity of honokiol-in-hydroxypropyl-β-cyclodextrin-in-liposome. Wang X; Deng L; Cai L; Zhang X; Zheng H; Deng C; Duan X; Zhao X; Wei Y; Chen L J Pharm Sci; 2011 Aug; 100(8):3357-3364. PubMed ID: 21387317 [TBL] [Abstract][Full Text] [Related]
10. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles. Hong M; Zhu S; Jiang Y; Tang G; Sun C; Fang C; Shi B; Pei Y J Control Release; 2010 Jan; 141(1):22-9. PubMed ID: 19735683 [TBL] [Abstract][Full Text] [Related]
11. DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting. Chang Q; Geng R; Wang S; Qu D; Kong X Drug Deliv; 2016 Nov; 23(9):3629-3638. PubMed ID: 27749106 [TBL] [Abstract][Full Text] [Related]
12. Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-β-cyclodextrin and safety evaluation. Jiang Y; Jiang X; Law K; Chen Y; Gu J; Zhang W; Xin H; Sha X; Fang X Int J Pharm; 2011 Aug; 415(1-2):252-8. PubMed ID: 21645594 [TBL] [Abstract][Full Text] [Related]
13. 9-nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats. Dadashzadeh S; Derakhshandeh K; Shirazi FH Anticancer Drugs; 2008 Sep; 19(8):805-11. PubMed ID: 18690092 [TBL] [Abstract][Full Text] [Related]
14. Soluplus(®) based 9-nitrocamptothecin solid dispersion for peroral administration: preparation, characterization, in vitro and in vivo evaluation. Lian X; Dong J; Zhang J; Teng Y; Lin Q; Fu Y; Gong T Int J Pharm; 2014 Dec; 477(1-2):399-407. PubMed ID: 25445521 [TBL] [Abstract][Full Text] [Related]
15. Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes. Zhang LJ; Xing B; Wu J; Xu B; Fang XL Pulm Pharmacol Ther; 2008; 21(1):239-46. PubMed ID: 17561423 [TBL] [Abstract][Full Text] [Related]
16. Comparative studies of the fate of free and liposome-entrapped hydroxypropyl-beta-cyclodextrin/drug complexes after intravenous injection into rats: implications in drug delivery. McCormack B; Gregoriadis G Biochim Biophys Acta; 1996 Dec; 1291(3):237-44. PubMed ID: 8980638 [TBL] [Abstract][Full Text] [Related]
17. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. Lu JL; Wang JC; Zhao SX; Liu XY; Zhao H; Zhang X; Zhou SF; Zhang Q Eur J Pharm Biopharm; 2008 Aug; 69(3):899-907. PubMed ID: 18434109 [TBL] [Abstract][Full Text] [Related]
18. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation. Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956 [TBL] [Abstract][Full Text] [Related]
19. Lactone stability and tissue distribution of free and liposomal encapsulated 9-nitrocamptothecin in rats following intravenous injection. Chen J; Cai B; Ping Q; Liu M; Guo J Drug Dev Ind Pharm; 2008 Aug; 34(8):853-9. PubMed ID: 18686092 [TBL] [Abstract][Full Text] [Related]
20. Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin. Chen J; Ping QN; Guo JX; Chu XZ; Song MM Drug Dev Ind Pharm; 2006 Jul; 32(6):719-26. PubMed ID: 16885127 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]